When to Order Imaging for Staging and Follow-up of Pancreatic Neuroendocrine Tumors: ACR Appropriateness Decoded

When to Order Imaging for Staging and Follow-up of Pancreatic Neuroendocrine Tumors: ACR Appropriateness Decoded

A patient presents with symptoms suggestive of a pancreatic neuroendocrine tumor (PNET), or has a known diagnosis requiring staging or surveillance. The choice of imaging is critical, balancing the need for detailed anatomical information, assessment of metastatic disease, and functional characterization of the tumor. Deciding between a multiphase computed tomography (CT), a magnetic resonance imaging (MRI) study, or a specialized nuclear medicine scan like DOTATATE PET/CT can be complex. Each modality offers unique advantages for visualizing the primary tumor, its relationship to adjacent vessels, and the presence of distant metastases, particularly in the liver. This guide breaks down the American College of Radiology (ACR) Appropriateness Criteria to help you select the most effective imaging pathway for your patient based on the specific clinical scenario, from initial local staging to long-term follow-up after treatment.

What Does ACR Staging and Follow-up of Pancreatic Neuroendocrine Tumors Cover?

This ACR guideline focuses on the use of diagnostic imaging for the initial staging, surveillance, and follow-up of well-differentiated pancreatic neuroendocrine tumors in adult patients. The criteria are organized into distinct clinical variants that address common decision points in the management of PNETs. These include initial local staging of a newly identified tumor, comprehensive evaluation for metastatic disease, routine surveillance after surgical resection in an asymptomatic patient, and follow-up imaging for both treated and untreated metastatic disease, with specific considerations for liver-dominant versus non-liver-dominant disease patterns. The recommendations are designed to guide clinicians in selecting the most appropriate imaging modality to assess tumor extent, guide treatment planning, and monitor for recurrence or progression. This document does not cover the initial detection of an unknown pancreatic mass or the evaluation of poorly differentiated neuroendocrine carcinomas, which have a different biological behavior and imaging approach.

What Imaging Should I Order for Staging and Follow-up of Pancreatic Neuroendocrine Tumors? Recommendations by Clinical Scenario

Choosing the right imaging study for a pancreatic neuroendocrine tumor depends entirely on the clinical question at hand—be it initial staging, searching for metastases, or post-treatment surveillance.

For the initial local staging of an adult with a pancreatic neuroendocrine tumor, several options are rated as Usually appropriate. A multiphase CT of the abdomen and pelvis with IV contrast is a cornerstone for evaluating the primary tumor and its relationship with surrounding vasculature. Similarly, DOTATATE PET/CT is highly valuable as it targets somatostatin receptors, which are overexpressed in most well-differentiated PNETs, providing both anatomical and functional information. A CT abdomen and pelvis without and with IV contrast is also Usually appropriate. Endoscopic ultrasound (EUS) is rated May be appropriate and is particularly useful for characterizing smaller tumors and guiding biopsy, though it is invasive and operator-dependent.

When the goal is a comprehensive evaluation for metastatic disease, the recommendations broaden. Both MRI of the abdomen and pelvis without and with IV contrast and CT of the abdomen and pelvis with IV contrast are Usually appropriate. MRI is often preferred for its superior sensitivity in detecting and characterizing liver metastases. DOTATATE PET/CT remains Usually appropriate for whole-body staging. To evaluate the chest for metastases, a CT of the chest, abdomen, and pelvis with IV contrast is also Usually appropriate.

For routine surveillance after surgical resection with no suspected recurrence, cross-sectional imaging is key. Both CT abdomen and pelvis with IV contrast and a more extensive CT chest, abdomen, and pelvis with IV contrast are considered Usually appropriate. The choice between them depends on the primary tumor’s risk profile and common sites of metastasis. In this surveillance setting, DOTATATE PET/CT is downgraded to May be appropriate, reserved for cases with higher suspicion of recurrence.

In the context of follow-up after treatment, the optimal imaging depends on the disease distribution. For liver-dominant disease, MRI of the abdomen and pelvis without and with IV contrast is Usually appropriate due to its high sensitivity for hepatic lesions. Multiphase CT scans of the abdomen/pelvis or chest/abdomen/pelvis are also Usually appropriate. For non-liver dominant disease, the list of Usually appropriate studies includes contrast-enhanced MRI, contrast-enhanced CT, and DOTATATE PET/CT, providing flexibility based on the location of disease and prior imaging findings. Finally, for follow-up of untreated disease, both multiphase CT and MRI options are Usually appropriate to monitor for disease progression.

ACR Imaging Recommendations Table

Adult vs. Pediatric Staging and Follow-up of Pancreatic Neuroendocrine Tumors Imaging: Radiation Dose Tradeoffs

While pancreatic neuroendocrine tumors are rare in children, the principles of imaging selection require special consideration for radiation dose. The ACR guidelines provide distinct relative radiation level (RRL) estimates for pediatric patients, reflecting a heightened commitment to the As Low As Reasonably Achievable (ALARA) principle. For example, a CT of the abdomen and pelvis with IV contrast carries an adult RRL of ☢ ☢ ☢ (1-10 mSv) but a pediatric RRL of ☢ ☢ ☢ ☢ (3-10 mSv [ped]). This difference highlights that the same organ dose can confer a higher lifetime attributable risk of malignancy in a younger patient due to the increased radiosensitivity of developing tissues and a longer lifespan over which potential stochastic effects could manifest.

Consequently, when clinical equipoise exists between modalities, there is often a stronger preference for non-ionizing options like MRI in pediatric patients. MRI avoids radiation exposure entirely and offers excellent soft tissue contrast, making it a powerful tool for evaluating the primary tumor and, critically, for detecting liver metastases. When CT is necessary, pediatric-specific protocols that reduce dose (e.g., lower kVp, automated tube current modulation) are essential to minimize cumulative radiation exposure from necessary surveillance scans over the patient’s lifetime.

Imaging Protocol Details for Staging and Follow-up of Pancreatic Neuroendocrine Tumors

Once you’ve decided on the right study based on the clinical scenario, ensuring it is performed correctly is the next critical step. The diagnostic yield of a CT or MRI for a pancreatic neuroendocrine tumor is highly dependent on the technical parameters, particularly the timing of intravenous contrast. Our protocol guides cover technique, contrast administration, and key interpretation principles for the studies recommended above:

• CT Chest/Abdomen/Pelvis with IV Contrast
• CT Abdomen/Pelvis Without Contrast (Renal Stone)

Tools to Help You Order the Right Study

Navigating imaging guidelines and protocols can be challenging. GigHz provides a suite of free reference tools designed to support clinical decision-making at the point of care. These resources help ensure that every imaging order is evidence-based, safe, and appropriate for the clinical question.

The ACR Appropriateness Criteria Lookup provides direct access to the full, searchable library of ACR guidelines, covering thousands of clinical scenarios beyond pancreatic neuroendocrine tumors. It’s designed to help you find the right study for any indication in seconds.

For detailed, step-by-step instructions on how to perform specific scans, the Imaging Protocol Library offers a comprehensive collection of standardized imaging protocols. This resource is invaluable for trainees and technologists aiming to optimize image quality and diagnostic accuracy.

To help manage and communicate radiation exposure with patients, the Radiation Dose Calculator allows for the estimation of effective dose from various CT scans. This tool supports informed conversations about the risks and benefits of imaging and helps in tracking cumulative exposure over time.

Frequently Asked Questions

Answers to common questions about imaging for pancreatic neuroendocrine tumors.

Why is DOTATATE PET/CT so important for pancreatic neuroendocrine tumors?

Well-differentiated neuroendocrine tumors, including most PNETs, overexpress somatostatin receptors (SSTRs) on their cell surfaces. DOTATATE is a peptide analog that binds with high affinity to these receptors. When labeled with a positron-emitting radionuclide like Gallium-68, it allows for highly sensitive and specific whole-body imaging of tumor sites. This makes Ga-68 DOTATATE PET/CT superior to traditional imaging for detecting occult metastases and confirming the neuroendocrine nature of lesions, which can significantly alter staging and treatment planning, including eligibility for peptide receptor radionuclide therapy (PRRT).

What is a “multiphase” CT and why is it necessary for the pancreas?

A multiphase CT involves acquiring images at several distinct time points after the injection of intravenous contrast material. For the pancreas, this typically includes a non-contrast phase, an early arterial phase (to see arteries and hypervascular tumors like PNETs), and a later portal venous phase (to see the portal vein and liver parenchyma). This technique is crucial because PNETs are often hypervascular and are most conspicuous during the arterial phase compared to the surrounding pancreatic tissue. The multiphase approach is essential for detecting the tumor, defining its extent, and assessing its relationship to critical blood vessels like the superior mesenteric artery and vein.

When is MRI preferred over CT for evaluating liver metastases from a PNET?

MRI, particularly with a liver-specific contrast agent (e.g., Eovist/Primovist), is generally considered more sensitive than CT for detecting and characterizing small liver metastases. The superior soft-tissue contrast of MRI allows for better differentiation between small tumors and benign lesions like cysts or hemangiomas. Therefore, MRI is often the preferred modality for initial staging when liver metastases are suspected and for follow-up of liver-dominant disease, as a more accurate assessment of the hepatic tumor burden is critical for treatment decisions.

Is endoscopic ultrasound (EUS) still relevant with advanced cross-sectional imaging?

Yes, EUS remains a very important tool, especially for specific indications. It is rated as May be appropriate for local staging. Its primary strengths are its extremely high spatial resolution for small pancreatic lesions (<2 cm) that may be missed by CT or MRI, and its ability to obtain tissue samples via fine-needle aspiration/biopsy (FNA/FNB) with high accuracy and safety. While not a whole-abdomen staging tool, it is invaluable for confirming a diagnosis, evaluating local lymph nodes, and characterizing small, indeterminate pancreatic lesions.

Why is FDG-PET/CT usually not the first choice for well-differentiated PNETs?

FDG-PET/CT measures glucose metabolism. Many well-differentiated, low-grade neuroendocrine tumors are slow-growing and have low metabolic activity, meaning they do not take up much FDG. This can lead to false-negative results. FDG-PET/CT is rated May be appropriate and becomes more useful in higher-grade, more aggressive, or poorly differentiated neuroendocrine tumors that have lost their somatostatin receptors and have become more metabolically active. In some cases, a tumor may be “flip-flop,” meaning it is DOTATATE-negative but FDG-positive, indicating more aggressive biology.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 12, 2026